TakeoverPE & activists

LRMRLarimar Therapeutics, Inc.

Pharmaceutical Preparations · $257M market cap

0.6×

Less likely than average to be taken private

Top 31% of the Russell 3000 for a buyout by a private-equity firm, holdco or insiders. How it works

Takeover signals

What an activist or buyer would see: cheap, overpaid, diluted or under pressure.

0of 15 firedHow well they predict deals →

No signals fired.

15 other checks
  • TSR below peersNo
    —
    3+ of last 5 years
  • High CEO pay despite TSRNo
    $3M median
    Median CEO pay ≥ $15M while TSR trails
  • Earnings not backed by cashNo
    —
    Cash flow under 80% of net income
  • Dilutive SBCNo
    —
    Over 10% of revenue
  • Payouts exceed cash flowNo
    0% of cash flow
    Buybacks + dividends over cash flow
  • Goodwill-heavyNo
    —
    Over 40% of assets
  • Shareholder dissentNo
    88% lowest support
    Any vote under 80% support
  • Low revenue per employeeNo
    —
    Bottom quartile of its SIC industry
  • Quiet on AINo
    1.9 per 10K words · 53rd pct
    Bottom quartile of AI mentions in 10-Ks
  • Net cashNo
    —
    More cash than debt, positive EBITDA
  • Buyout-sizedNo
    $257M market cap
    Market cap $500M–$5B
  • Recurring revenueNo
    0 of 10
    10-K business scored 7+ of 10 for recurring revenue
  • AI-rollup shapedNo
    0 of 10
    10-K business scored 5+ of 10 as an AI-rollup target
  • Active 13DNo
    0 filings
    Active-intent 13D in 18 months
  • Net insider sellingNo
    $26M net
    Net sales over $10M in 12 months

Deal filings

FiledFormAcquirerPricePremium
Apr 29, 2020DEFM14AChondrial Therapeutics, Inc.$645.51—
Mar 6, 2020PREM14AChondrial Therapeutics, Inc.$1.1864.55%

Key numbers

Revenue
—
Operating margin
—
EBITDA
−$172MFY2021: −$50MFY2022: −$36MFY2023: −$41MFY2024: −$91MFY2025: −$172M
90% YoY
Net debt / EBITDA
—
−$78M net debt

Financials

MetricFY2021FY2022FY2023FY2024FY2025YoYTrend
Operating income−$50M−$37M−$42M−$91M−$172M 90% FY2021: −$50MFY2022: −$37MFY2023: −$42MFY2024: −$91MFY2025: −$172M
Net income−$51M−$35M−$37M−$81M−$166M 106% FY2021: −$51MFY2022: −$35MFY2023: −$37MFY2024: −$81MFY2025: −$166M
Operating cash flow−$42M−$28M−$33M−$71M−$113M 60% FY2021: −$42MFY2022: −$28MFY2023: −$33MFY2024: −$71MFY2025: −$113M
Capex$333K$100K$164K$515K$91K 82% FY2021: $333KFY2022: $100KFY2023: $164KFY2024: $515KFY2025: $91K
Stock-based comp$5M$7M$8M$9M$7M 20% FY2021: $5MFY2022: $7MFY2023: $8MFY2024: $9MFY2025: $7M

13D filers

FiledFilerFormStakeIntent
Mar 2, 2026Flynn James ESCHEDULE 13D/A34.4%Passive
Jul 31, 2025Flynn James ESCHEDULE 13D/A35.8%Passive
Mar 15, 2024Flynn James ESC 13D/A33.3%Passive
Feb 16, 2024Flynn James ESC 13D/A34.8%Passive
Feb 15, 2024Flynn James ESC 13D/A10.8%Passive
Mar 17, 2023Flynn James ESC 13D/A10.9%Passive
Sep 16, 2022Flynn James ESC 13D/A11.8%Passive
Jul 2, 2021Flynn James ESC 13D/A11.0%Passive
May 26, 2021Flynn James ESC 13D/A33.5%Passive
May 21, 2021Flynn James ESC 13D/A11.2%Passive

Insider trading

+$26Mnet buying by insiders, open market, last 12 months
Bought $26M · 8 tradesSold $0 · 0 trades

Pay vs performance

YearCEO total compComp actually paidTSR (indexed)Peer TSR
FY2025$4M$2M36—
FY2024$3M$2M36—
FY2023$3M$3M42—